In this proof-of-principle study of 12 people with moderate-to-severe major depressive disorder, MDMA-assisted therapy was associated with significant improvements in psychological wellbeing, self-compassion and alexithymia (difficulty identifying and describing emotions), with gains maintained at follow-up. Eight participants had borderline or higher alexithymia at baseline, compared with none at follow-up. Improvements were driven by the nine participants who responded to treatment. The findings suggest that MDMA-assisted therapy may support emotional awareness and a more compassionate relationship with oneself, alongside improvements in depression. However, the study was small and open-label, with no control group, so the results are preliminary and cannot establish that MDMA itself caused the improvements
Abstract
Background
Transdiagnostic factors such as emotion regulation, self-compassion, and alexithymia influence the development and outcome of psychiatric conditions, including major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). 3,4-Methylenedioxymethamphetamine-assisted therapy (MDMA-AT) has shown efficacy in reducing PTSD and depressive symptoms. This study examined MDMA-AT effects on alexithymia, self-compassion, and well-being in MDD, assessing durability and links to long-term outcomes.
Methods
Data were drawn from an open-label MDMA-AT trial (EudraCT 2021-000805-26) including twelve participants with moderate to severe MDD (baseline MADRS M(SD) = 29.6(4.9)). Participants received two MDMA sessions with manualized psychotherapy (three preparatory, six integration). Outcomes were assessed at baseline, post-treatment (8 weeks), and long-term follow-up (≥3 months) using the Toronto Alexithymia Scale (TAS-20), Self-Compassion Scale (SCS), and Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). Changes were analyzed with linear mixed models; estimated marginal means and post-hoc comparisons explored time effects.
Results
MDMA-AT significantly improved alexithymia, self-compassion, and well-being. TAS-20 decreased by −11.75 post-treatment and −16.42 at follow-up (both p < 0.001). SCS increased by 0.73 post-treatment (p = 0.017) and 1.07 at follow-up (p = 0.001). WEMWBS improved by 17.30 at both timepoints (p < 0.001). All SCS subscales improved; common humanity and isolation reached significance only at follow-up. Improvements were driven by therapy responders (9/12). Eight participants had at least borderline alexithymia at baseline; none did at follow-up. Self-compassion shifted from seven low and one high at baseline to seven high and one low at follow-up.
Conclusions
MDMA-AT for MDD produced lasting improvements in alexithymia, self-compassion, and well-being, supporting its potential for durable psychological recovery beyond symptom reduction
Berthold-Losleben, M., Goksøyr, I.W., Kvam, T.-M., Rog, J., Stewart, L.H., Scarth, M. and Andreassen, O.A. (2026). Changes in wellbeing, self-compassion and alexithymia in a proof of principle trial with MDMA-assisted therapy for major depressive disorder. Journal of Psychiatric Research, 204, 493–501. Read Paper